UBX News and Press, Unity Biotechnology Inc. From 03/15/22

Unity Biotechnology press release (NASDAQ:UBX): Q4 GAAP EPS of -$0.18 beats by $0.18. Revenue of $4.78M. Cash, cash equivalents and marketable securities totaled $90.1 million as of December 31, 2021 compared with $115.6 million as of December 31, 2020 For further details see: Unity Bio...

SOUTH SAN FRANCISCO, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the fourth quarter and full year ended December 3...

SOUTH SAN FRANCISCO, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that members of its senior management team will provi...

UNITY Biotechnology (UBX +14.7%) announced 24-week data from its Phase 1 study for UBX1325 in patients with diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD). The disclosure on Monday followed a presentation made by Robert Bhisitkul, M.D. professor of ophthalmolo...

24-week UBX1325 Phase 1 data presented at Angiogenesis, Exudation, and Degeneration 2022 Conference Patients with diabetic macular edema (DME) and wet age-related macular degeneration (wAMD) showed improvement in visual acuity through 24 weeks following single dose of UBX1325 ...

UNITY Biotechnology (NASDAQ:UBX) slid 9% postmarket after it said initiated a restructuring program to align its resources on later-stage programs in ophthalmology while further extending operating capital into Q1 2023. These measures will enable UBX to achieve multiple key clinical data...

Strategic realignment to focus capital resources on clinical programs and extend cash runway into Q1 2023 12-week data from Phase 2a study of UBX1325 in diabetic macular edema (DME) expected mid-2022 16-week data from Phase 2 study in wet age-related macular degeneration...

12-week safety and efficacy analysis from a Phase 2 study of UBX1325 in diabetic macular edema (DME) expected in first half 2022 and wet age-related macular degeneration (wet AMD) expected in the second half of 2022 Phase 2 study of UBX1325 in wet AMD to include comparison with ...

SOUTH SAN FRANCISCO, Calif., Dec. 20, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced it has signed an exclusive agreement licensing its &#x...

The Nasdaq Biotechnology Index will have a new look on December 20, before the market opens when 129 securities will be added and 21 securities will be deleted as part of the annual reconstitution. Notable additions to the index: Viatris (NASDAQ:VTRS), NovoCure (NASDAQ:NVCR), Anavex Life Scie...